Ciclesonide for the treatment of airway hyperresponsiveness
Study identifier:BY9010/CH-101
ClinicalTrials.gov identifier:NCT00826969
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Ciclesonide for the treatment of airway hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A double-blind, randomized, parallel group study.
Medical condition
asthma
Phase
Phase 4
Healthy volunteers
No
Study drug
Ciclesonide, Placebo
Sex
All
Actual Enrollment
64
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 Sept 2008
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Oct 2011
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Ciclesonide 320µg | Drug: Ciclesonide 320µg Ciclesonide versus Placebo |
| Placebo Comparator: 2 Placebo | Drug: Placebo Placebo |
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
